includes:trial - GLP1 Guide

drug:orforglipron

We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly

drug:cagrisema

We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s

drug:mounjaro

Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.

drug:phentermine

Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?

drug:orforglipron

MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.

category:news

We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.

drug:eloralinitide

We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.

research

Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.

category:benefits

We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.

chemical:semaglutide

Semaglutide and Liraglutide continue to be researched and studied and produce positive results for weight loss and medical outcomes.

drug:am-133

Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.

company:eli-lilly

Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.